New drug could tame rare muscle disease and cut steroid use
NCT ID NCT04972760
First seen Jun 08, 2026 · Last updated Jun 22, 2026 · Updated 4 times
Summary
This Phase 3 trial tests baricitinib, a JAK inhibitor pill, in 62 adults with dermatomyositis, a rare disease causing muscle weakness and skin rashes. The goal is to see if baricitinib can improve symptoms and allow patients to stop steroids. Participants receive baricitinib or placebo for 24 weeks alongside standard care.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DERMATOMYOSITIS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Pitie-Salpêtrière hospital APHP
RECRUITINGParis, 75013, France
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Baricitinib (a JAK inhibitor drug taken as a pill)
What this could lead to
If it works, baricitinib could offer a new treatment option for dermatomyositis that helps control the disease with less reliance on steroids.
What could go wrong
This is a relatively small Phase 3 trial (62 people), and baricitinib may not prove more effective than placebo. Side effects of JAK inhibitors include infection risk.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.